BiotechTube

Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases

Trial Timeline

Nov 28, 2017 → May 1, 2021

NCT ID
NCT03296540

About Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)

Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) is a approved stage product being developed by Daiichi Sankyo for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03296540. Target conditions include Cardiovascular Diseases.

What happened to similar drugs?

20 of 20 similar drugs in Cardiovascular Diseases were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Empagliflozin + PlacebosEli LillyApproved
✅Aspirin + Placebo + ticagrelorAstraZenecaApproved
✅Rosuvastatin Oral TabletAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03296540ApprovedCompleted

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
Midazolam + AZD5718AstraZenecaPhase 1
29